221 related articles for article (PubMed ID: 12764500)
1. No deal in sight on cheap drugs for poor countries.
Fleck F
Bull World Health Organ; 2003; 81(4):307-8. PubMed ID: 12764500
[No Abstract] [Full Text] [Related]
2. Ensuring access to essential medicines: some economic considerations.
Maskus KE
Spec Law Dig Health Care Law; 2003 Jul; (291):9-25. PubMed ID: 15206162
[No Abstract] [Full Text] [Related]
3. Access to essential drugs, human rights and global justice.
Shalev C
Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
[No Abstract] [Full Text] [Related]
4. World pharmaceutical developments.
Bale H
World Hosp Health Serv; 2002; 38(2):1. PubMed ID: 12402745
[No Abstract] [Full Text] [Related]
5. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
6. Deadlock on access to cheap drugs at global trade negotiations.
Hagmann M
Bull World Health Organ; 2003; 81(2):150-1. PubMed ID: 12751424
[No Abstract] [Full Text] [Related]
7. Innovation and the WHO's essential medicines list: giving credit where credit is due.
Wertheimer AI; Santella TM
Res Social Adm Pharm; 2007 Mar; 3(1):137-44. PubMed ID: 17350562
[No Abstract] [Full Text] [Related]
8. Ethics and AIDS drugs.
Dowell W
Time; 1999 Jul; 154(2):49. PubMed ID: 10538646
[No Abstract] [Full Text] [Related]
9. Drugs and vaccines around the world.
Health Aff (Millwood); 2006; 25(2):312. PubMed ID: 16522572
[No Abstract] [Full Text] [Related]
10. [Access for all to quality drugs].
Videau JY
Med Trop (Mars); 2002; 62(4):396-400. PubMed ID: 12534178
[TBL] [Abstract][Full Text] [Related]
11. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
12. The responsibility of research universities to promote access to essential medicines.
't Hoen EF
Yale J Health Policy Law Ethics; 2003; 3(2):293-300. PubMed ID: 14577145
[No Abstract] [Full Text] [Related]
13. No money, no meds.
Mabry M
Newsweek; 1999 Jul; 134(2):32-3. PubMed ID: 10538648
[No Abstract] [Full Text] [Related]
14. The GO License: only part of the solution.
Batson A; Milstien JB
Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
[TBL] [Abstract][Full Text] [Related]
15. EU launches measures to stop diversion of cut-price drugs.
Fleck F
Bull World Health Organ; 2003; 81(7):549. PubMed ID: 12973652
[No Abstract] [Full Text] [Related]
16. Drug prices may be too high despite WTO deal.
Fleck F
Bull World Health Organ; 2003; 81(10):774-5. PubMed ID: 14758442
[No Abstract] [Full Text] [Related]
17. A fair deal for the future: flexibilities under TRIPS.
So AD
Bull World Health Organ; 2004 Nov; 82(11):813. PubMed ID: 15640914
[No Abstract] [Full Text] [Related]
18. Drug companies should cut prices for developing countries, says G8 report.
Walgate R
Bull World Health Organ; 2003; 81(1):72-3. PubMed ID: 12640481
[No Abstract] [Full Text] [Related]
19. Policy watch. Profitable pills.
Gebbie KM
AIDS Read; 2004 Mar; 14(3):106, 109. PubMed ID: 15067998
[No Abstract] [Full Text] [Related]
20. Access to essential drugs prevented by pharmaceutical multinationals.
Dev World Bioeth; 2001 May; 1(1):1-6. PubMed ID: 12870503
[No Abstract] [Full Text] [Related]
[Next] [New Search]
